|
An evaluation of serotonergic genes polymorphism in the antidepressant response of major depressive disorder patients treated with escitalopram and venlafaxine
|
|
| Author:
|
SUBRAMANIAN RASHMI, ALAGAR YADAV SANGILIMUTHU, VENKATESH KUMAR, JEYAN
|
| Abstract:
|
In pharmacogenetic research, examining the relationship between serotonergic genes and antidepressant response of Major Depressive Disorder (MDD) patients plays a vital role for better treatment of Major Depressive Disorder. Pharmacogenetic study provide the clinical detail of patients to treat patient specific treatment. Several studies have suggested that differences in treatment response to antidepressant therapy may help to create clinically meaningful and genetic based subgroups among Major Depressive Disorder patients. The present study aimed at testing the potential effect of serotonergic genes polymorphism (5HTTLPRS-S/L, TPH1-A218C and TPH2-G703T)on MDD patients with poor and good therapeutic responses.162 Major Depressive Disorder patients were enrolled and genotyped for 5HTTLPRS (S/L), TPH1 (A218C) and TPH2 (G703T) polymorphism. In these randomized trials, patients received either escitalopram or venlaflaxine treatment. Symptoms and severity were accessed at weeks2, 4 and 6 using 17-item Hamilton Depression Rating Scale (HAMD-17).Our results show that the association between 5HTTLPR, TPH1-A218C, and TPH2-G703Tgenotype was less significant in Major Depressive Disorder patient’s response to escialopram/venlafaxine treatment.The proportion of 5HTTLPR S allele, TPH1 A allele, TPH2 G allele was higher in escitalopram/venlafaxine treatment groups than non-treatment group. Our data reveals that, better response in S allele of 5HTTLPR and TPH1 A allele and TPH2 G allele carriers to escitalopram / venlafaxine treatment. The extensive knowledge in this study can make clinical use of the genetic profile as predictor possible. This makes it possible to identify the best therapeutic tool and to avoid long term treatment.
|
| Keyword:
|
Antidepressant, Serotonin, Major Depressive Disorder, Tryptophan Hydroxylase 1and 2.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP2.054
|
| Download:
|
Request For Article
|
|
|